The market for treating vaginal and vulval inflammatory diseases is expected to reach US$ 2.96 billion in fiscal year 2023, up from US$ 2.8 billion in fiscal year 2022. The global market is expected to grow steadily at a 5.8% CAGR between 2023 and 2033, reaching a value of US$ 5.21 billion by the end of that year. Among the symptoms of vaginal and vulval inflammation are swelling around the...